ACUC Stock Overview
AcuCort AB (publ) develops and commercializes glucocorticoid dexamethasone films for the treatment of acute allergic conditions.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
AcuCort AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | kr0.50 |
52 Week High | kr2.05 |
52 Week Low | kr0.33 |
Beta | 0.62 |
1 Month Change | 27.27% |
3 Month Change | 28.24% |
1 Year Change | -71.20% |
3 Year Change | -89.63% |
5 Year Change | -92.59% |
Change since IPO | -89.50% |
Recent News & Updates
Recent updates
Shareholder Returns
ACUC | SE Pharmaceuticals | SE Market | |
---|---|---|---|
7D | 22.6% | 3.7% | 2.0% |
1Y | -71.2% | 80.3% | 17.8% |
Return vs Industry: ACUC underperformed the Swedish Pharmaceuticals industry which returned 80.2% over the past year.
Return vs Market: ACUC underperformed the Swedish Market which returned 18% over the past year.
Price Volatility
ACUC volatility | |
---|---|
ACUC Average Weekly Movement | 8.0% |
Pharmaceuticals Industry Average Movement | 7.4% |
Market Average Movement | 6.1% |
10% most volatile stocks in SE Market | 13.1% |
10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: ACUC's share price has been volatile over the past 3 months.
Volatility Over Time: ACUC's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2006 | 3 | Jonas Jonmark | https://www.acucort.com |
AcuCort AB (publ) develops and commercializes glucocorticoid dexamethasone films for the treatment of acute allergic conditions. It offers Zeqmelit, a medicine used for the treatment of severe and acute allergic reactions, croup in children, and chemotherapy-induced nausea and vomiting, as well as for the treatment of COVID-19 patients who need supplemental oxygen treatment. AcuCort AB (publ) was incorporated in 2006 and is based in Lund, Sweden.
AcuCort AB (publ) Fundamentals Summary
ACUC fundamental statistics | |
---|---|
Market cap | kr42.34m |
Earnings (TTM) | -kr13.69m |
Revenue (TTM) | kr6.59m |
6.4x
P/S Ratio-3.1x
P/E RatioIs ACUC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ACUC income statement (TTM) | |
---|---|
Revenue | kr6.59m |
Cost of Revenue | kr0 |
Gross Profit | kr6.59m |
Other Expenses | kr20.28m |
Earnings | -kr13.69m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.16 |
Gross Margin | 100.00% |
Net Profit Margin | -207.69% |
Debt/Equity Ratio | 0% |
How did ACUC perform over the long term?
See historical performance and comparison